JP7101419B2 - 内因性t細胞受容体の標的置換 - Google Patents
内因性t細胞受容体の標的置換 Download PDFInfo
- Publication number
- JP7101419B2 JP7101419B2 JP2020523254A JP2020523254A JP7101419B2 JP 7101419 B2 JP7101419 B2 JP 7101419B2 JP 2020523254 A JP2020523254 A JP 2020523254A JP 2020523254 A JP2020523254 A JP 2020523254A JP 7101419 B2 JP7101419 B2 JP 7101419B2
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- heterologous
- cell
- cells
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022103225A JP2022137112A (ja) | 2017-10-27 | 2022-06-28 | 内因性t細胞受容体の標的置換 |
| JP2024152864A JP2024174943A (ja) | 2017-10-27 | 2024-09-05 | 内因性t細胞受容体の標的置換 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762578153P | 2017-10-27 | 2017-10-27 | |
| US62/578,153 | 2017-10-27 | ||
| PCT/US2018/058026 WO2019084552A1 (en) | 2017-10-27 | 2018-10-29 | TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022103225A Division JP2022137112A (ja) | 2017-10-27 | 2022-06-28 | 内因性t細胞受容体の標的置換 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500889A JP2021500889A (ja) | 2021-01-14 |
| JP2021500889A5 JP2021500889A5 (cg-RX-API-DMAC7.html) | 2021-12-09 |
| JP7101419B2 true JP7101419B2 (ja) | 2022-07-15 |
Family
ID=66247037
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523254A Active JP7101419B2 (ja) | 2017-10-27 | 2018-10-29 | 内因性t細胞受容体の標的置換 |
| JP2022103225A Ceased JP2022137112A (ja) | 2017-10-27 | 2022-06-28 | 内因性t細胞受容体の標的置換 |
| JP2024152864A Pending JP2024174943A (ja) | 2017-10-27 | 2024-09-05 | 内因性t細胞受容体の標的置換 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022103225A Ceased JP2022137112A (ja) | 2017-10-27 | 2022-06-28 | 内因性t細胞受容体の標的置換 |
| JP2024152864A Pending JP2024174943A (ja) | 2017-10-27 | 2024-09-05 | 内因性t細胞受容体の標的置換 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US11033584B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3700924A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7101419B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102770787B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN111655719A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018355587B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3080415A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202091056A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL274179B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020004325A (cg-RX-API-DMAC7.html) |
| MY (1) | MY201694A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202003798TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019084552A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200418A (en) | 2017-06-15 | 2023-12-25 | Univ California | Targeted non-viral dna insertions |
| SG11202003798TA (en) * | 2017-10-27 | 2020-05-28 | Univ California | Targeted replacement of endogenous t cell receptors |
| EP3703712A4 (en) | 2017-10-30 | 2021-09-22 | PACT Pharma, Inc. | EDITING PRIMARY CELL GENES |
| KR20200138334A (ko) | 2018-04-02 | 2020-12-09 | 팩트 파마, 인크. | 펩티드-MHC comPACT |
| CN112585277A (zh) * | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 表达重组受体的t细胞、相关多核苷酸和方法 |
| US20210207174A1 (en) * | 2018-05-25 | 2021-07-08 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
| IL316576A (en) | 2019-02-12 | 2024-12-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| AU2020325225A1 (en) * | 2019-08-05 | 2022-03-24 | Cartherics Pty. Ltd. | Immune cells expressing modified cell receptors and methods of making |
| EP3808765A1 (en) * | 2019-10-14 | 2021-04-21 | ETH Zurich | Cell line for tcr discovery and engineering and methods of use thereof |
| JPWO2021095847A1 (cg-RX-API-DMAC7.html) * | 2019-11-14 | 2021-05-20 | ||
| CA3157411A1 (en) * | 2019-11-15 | 2021-05-20 | Karin Jooss | Antigen-binding proteins targeting shared neoantigens |
| BR112022018218A2 (pt) * | 2020-03-13 | 2022-12-20 | Univ California | Composições e métodos para modificar um ácido nucleico alvo |
| WO2022047003A1 (en) * | 2020-08-27 | 2022-03-03 | Tmunity Therapeutics Inc. | Vector-free process for manufacture of engineered immune cells |
| JP2023544161A (ja) * | 2020-10-02 | 2023-10-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんの改善されたt細胞免疫療法のためのdna構築物 |
| TW202309272A (zh) * | 2021-03-24 | 2023-03-01 | 美商建南德克公司 | T淋巴球中之高效tcr基因編輯 |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| CN119486759A (zh) * | 2022-02-14 | 2025-02-18 | 加利福尼亚大学董事会 | 用于改善t细胞免疫疗法的dna构建体 |
| CN119677842A (zh) * | 2022-03-17 | 2025-03-21 | 科士华(南京)生物技术有限公司 | 人工合成肿瘤浸润淋巴细胞 |
| CR20250095A (es) | 2022-09-13 | 2025-09-01 | Arsenal Biosciences Inc | Células inmunitarias que coexpresan arnhc de tgfbr |
| JP2025532585A (ja) | 2022-09-16 | 2025-10-01 | アーセナル バイオサイエンシズ インコーポレイテッド | 組み合わせ遺伝子摂動を有する免疫細胞 |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| CN121127257A (zh) * | 2023-02-03 | 2025-12-12 | Affini-T治疗有限公司 | 携带kras结合蛋白并敲除内源性tcr的宿主细胞及其使用方法 |
| US20260232734A1 (en) | 2023-02-27 | 2026-08-13 | Adaptive Biotechnologies Corporation | Therapeutic T-Cell Receptors Targeting KRAS G12D |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向psma及ca9之系統 |
| EP4680748A1 (en) | 2023-03-13 | 2026-01-21 | Arsenal Biosciences, Inc. | Synthetic pathway activators |
| WO2025193663A2 (en) * | 2024-03-11 | 2025-09-18 | Affini-T Therapeutics, Inc. | Compositions and methods for treating neoplasia |
| TW202544044A (zh) | 2024-03-20 | 2025-11-16 | 美商亞森諾生物科學公司 | 靶向slc34a2及tmprss4之系統及其使用方法 |
| WO2025199346A1 (en) | 2024-03-20 | 2025-09-25 | Arsenal Biosciences, Inc. | Antigen binding proteins that bind tmprss4 and methods of use thereof |
| WO2026055342A1 (en) | 2024-09-04 | 2026-03-12 | Arsenal Biosciences, Inc. | Synthetic pathway activators |
| WO2026136848A2 (en) | 2024-12-20 | 2026-06-25 | Juno Therapeutics, Inc. | Cd70-targeted cars and engineered cells comprising same and related methods |
| WO2026151965A1 (en) | 2025-01-10 | 2026-07-16 | Arsenal Biosciences, Inc. | Shrna targeting fas and tgfbrii genes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014153470A2 (en) | 2013-03-21 | 2014-09-25 | Sangamo Biosciences, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| WO2017106528A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the t cell receptor |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
| US6090617A (en) | 1996-12-05 | 2000-07-18 | Entremed, Inc. | Flow electroporation chamber with electrodes having a crystalline metal nitride coating |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| JP2003531616A (ja) | 2000-04-28 | 2003-10-28 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 細胞性クロマチンに外因性分子を結合させるための方法 |
| US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
| JP4070611B2 (ja) | 2001-04-23 | 2008-04-02 | アマクサ アーゲー | 電気穿孔法用の緩衝溶液およびその使用を含む方法 |
| DK2574662T3 (da) | 2001-08-22 | 2021-09-20 | Maxcyte Inc | Fremgangsmåde til elektroporation af biologiske prøver |
| US20050136040A1 (en) | 2001-10-11 | 2005-06-23 | Imperial College Innovations Limited | Control of gene expression using a complex of an oligonucleotide and a regulatory peptide |
| GB0124391D0 (en) | 2001-10-11 | 2001-11-28 | Gene Expression Technologies L | Control of gene expression |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| ITMI20030821A1 (it) | 2003-04-18 | 2004-10-19 | Internat Ct For Genetic En Gineering And | Polipeptidi chimerici e loro uso. |
| CN1836048A (zh) | 2003-06-10 | 2006-09-20 | 图尔金株式会社 | 可转导的dna结合蛋白 |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| DE502004009820D1 (de) | 2004-03-15 | 2009-09-10 | Lonza Cologne Ag | Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen |
| WO2005113820A2 (en) | 2004-05-12 | 2005-12-01 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
| RU2006143560A (ru) | 2004-06-12 | 2008-07-20 | Диджитал Био Технолоджи Ко | Устройство для электропорации с удлиненным полым элементом |
| ES2465467T3 (es) | 2004-06-14 | 2014-06-05 | Lonza Cologne Ag | Procedimiento y disposición de circuito para el tratamiento de material biológico |
| WO2005123962A2 (en) | 2004-06-14 | 2005-12-29 | The University Of Texas At Austin | Gene targeting in eukaryotic cells by group ii intron ribonucleoprotein particles |
| JP2008521437A (ja) | 2004-11-30 | 2008-06-26 | マックスサイト インコーポレーティッド | コンピュータ化されたエレクトロポレーション |
| US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| EP2325332B1 (en) | 2005-08-26 | 2012-10-31 | DuPont Nutrition Biosciences ApS | Use of CRISPR associated genes (CAS) |
| JP2010500029A (ja) | 2006-08-11 | 2010-01-07 | ダウ アグロサイエンシィズ エルエルシー | ジンクフィンガーヌクレアーゼ媒介相同組換え |
| JP5779090B2 (ja) | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| EP2310500B1 (en) | 2008-07-18 | 2015-03-11 | Maxcyte, Inc. | Methods for optimizing electroporation |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| WO2010129023A2 (en) | 2009-04-28 | 2010-11-11 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| US9567573B2 (en) | 2010-04-26 | 2017-02-14 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using nucleases |
| US8876458B2 (en) | 2011-01-25 | 2014-11-04 | United Technologies Corporation | Blade outer air seal assembly and support |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| US20130236504A1 (en) | 2012-03-06 | 2013-09-12 | Medical University Of South Carolina | Delivery System for Enhancing Drug Efficacy |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| EP4397759A3 (en) | 2012-10-23 | 2024-10-09 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| CN105408483A (zh) | 2013-03-15 | 2016-03-16 | 通用医疗公司 | 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向 |
| CA2906218A1 (en) * | 2013-03-15 | 2014-09-18 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
| CN105121650A (zh) | 2013-04-02 | 2015-12-02 | 拜尔作物科学公司 | 真核生物中的靶向基因组工程 |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法 |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| WO2015048690A1 (en) | 2013-09-27 | 2015-04-02 | The Regents Of The University Of California | Optimized small guide rnas and methods of use |
| EP3058072B1 (en) | 2013-10-17 | 2021-05-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| US9951353B2 (en) | 2013-11-15 | 2018-04-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Engineering neural stem cells using homologous recombination |
| JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物 |
| WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| CN111206032B (zh) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| JP2016539653A (ja) | 2013-12-13 | 2016-12-22 | セレクティス | 微小藻類のゲノム操作のためのCas9ヌクレアーゼプラットフォーム |
| KR102415811B1 (ko) | 2014-01-31 | 2022-07-04 | 팩터 바이오사이언스 인크. | 핵산 제조 및 송달을 위한 방법 및 산물 |
| WO2015115903A1 (en) | 2014-02-03 | 2015-08-06 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Site-specific dna break-induced genome editing using engineered nucleases |
| SG11201608701QA (en) | 2014-04-18 | 2016-11-29 | Editas Medicine Inc | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| WO2016036754A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification |
| US20160081314A1 (en) * | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
| CN113930455A (zh) | 2014-10-09 | 2022-01-14 | 生命技术公司 | Crispr寡核苷酸和基因剪辑 |
| KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| WO2016097751A1 (en) | 2014-12-18 | 2016-06-23 | The University Of Bath | Method of cas9 mediated genome engineering |
| EP3247328B1 (en) | 2015-01-21 | 2026-01-07 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| US20190388469A1 (en) | 2015-01-30 | 2019-12-26 | The Regents Of The University Of California | Protein delivery in primary hematopoietic cells |
| US12129471B2 (en) | 2015-02-23 | 2024-10-29 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
| WO2016172359A2 (en) | 2015-04-24 | 2016-10-27 | The Regents Of The University Of California | Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them |
| MX2017015239A (es) | 2015-05-29 | 2018-02-19 | Juno Therapeutics Inc | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. |
| US11555207B2 (en) | 2015-06-17 | 2023-01-17 | The Uab Research Foundation | CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| EP3310932B1 (en) | 2015-06-17 | 2023-08-30 | The UAB Research Foundation | Crispr/cas9 complex for genomic editing |
| US20170000743A1 (en) | 2015-07-02 | 2017-01-05 | Vindico NanoBio Technology Inc. | Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles |
| CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2017035659A1 (en) | 2015-09-01 | 2017-03-09 | The Hospital For Sick Children | Method and compositions for removing duplicated copy number variations (cnvs) for genetic disorders and related uses |
| KR20180043800A (ko) * | 2015-09-09 | 2018-04-30 | 이뮨 디자인 코포레이션 | Ny-eso-1 특이적 tcrs 및 그의 사용 방법 |
| WO2017053729A1 (en) | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
| US11286480B2 (en) | 2015-09-28 | 2022-03-29 | North Carolina State University | Methods and compositions for sequence specific antimicrobials |
| ES2768984T3 (es) * | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| ES2803728T3 (es) * | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| WO2017070169A1 (en) | 2015-10-19 | 2017-04-27 | The Methodist Hospital | Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation |
| US20180312873A1 (en) | 2015-10-20 | 2018-11-01 | 10X Genomics, Inc. | Method and systems for high throughput single cell genetic manipulation |
| WO2017070429A1 (en) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
| US12642852B1 (en) | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| AU2016359629B2 (en) | 2015-11-23 | 2023-03-09 | Ranjan BATRA | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9 |
| EP3397760A2 (en) | 2015-12-30 | 2018-11-07 | Avectas Limited | Vector-free delivery of gene editing proteins and compositions to cells and tissues |
| US20190241910A1 (en) * | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| AU2017248259A1 (en) | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
| EP4166161B1 (en) | 2016-04-14 | 2026-03-04 | Fred Hutchinson Cancer Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| KR102614675B1 (ko) * | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| WO2017189336A1 (en) | 2016-04-25 | 2017-11-02 | The Regents Of The University Of California | Methods and compositions for genomic editing |
| KR102370675B1 (ko) | 2016-04-29 | 2022-03-04 | 바스프 플랜트 사이언스 컴퍼니 게엠베하 | 표적 핵산의 변형을 위한 개선된 방법 |
| WO2017210334A1 (en) | 2016-05-31 | 2017-12-07 | Massachusetts Institute Of Technology | Hydrodynamically controlled electric fields for high throughput transformation & high throughput parallel transformation platform |
| US11713458B2 (en) | 2016-06-20 | 2023-08-01 | Octapharma Ag | Means and methods for modifying multiple alleles |
| WO2018035387A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| WO2018039084A1 (en) | 2016-08-20 | 2018-03-01 | The Regents Of The University Of California | High-throughput system and method for the temporary permeablization of cells |
| AU2017341736B2 (en) | 2016-10-12 | 2022-09-08 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| AU2017362513A1 (en) | 2016-11-18 | 2019-05-16 | Christopher Bradley | Massively multiplexed homologous template repair for whole-genome replacement |
| RU2019121801A (ru) | 2016-12-14 | 2021-01-15 | Лигандал, Инк. | Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка |
| CN110546495B (zh) | 2016-12-30 | 2022-11-01 | 加利福尼亚州立大学董事会 | 用于基因组编辑t细胞的选择和传代的方法 |
| MY200418A (en) | 2017-06-15 | 2023-12-25 | Univ California | Targeted non-viral dna insertions |
| SG11202003798TA (en) * | 2017-10-27 | 2020-05-28 | Univ California | Targeted replacement of endogenous t cell receptors |
| EP3703712A4 (en) | 2017-10-30 | 2021-09-22 | PACT Pharma, Inc. | EDITING PRIMARY CELL GENES |
-
2018
- 2018-10-29 SG SG11202003798TA patent/SG11202003798TA/en unknown
- 2018-10-29 CA CA3080415A patent/CA3080415A1/en active Pending
- 2018-10-29 CN CN201880084419.6A patent/CN111655719A/zh active Pending
- 2018-10-29 IL IL274179A patent/IL274179B2/en unknown
- 2018-10-29 KR KR1020237005926A patent/KR102770787B1/ko active Active
- 2018-10-29 JP JP2020523254A patent/JP7101419B2/ja active Active
- 2018-10-29 MX MX2020004325A patent/MX2020004325A/es unknown
- 2018-10-29 AU AU2018355587A patent/AU2018355587B2/en active Active
- 2018-10-29 CN CN202410674648.0A patent/CN118581047A/zh active Pending
- 2018-10-29 KR KR1020207015078A patent/KR102503130B1/ko active Active
- 2018-10-29 EA EA202091056A patent/EA202091056A1/ru unknown
- 2018-10-29 WO PCT/US2018/058026 patent/WO2019084552A1/en not_active Ceased
- 2018-10-29 EP EP18871537.9A patent/EP3700924A4/en active Pending
- 2018-10-29 MY MYPI2020002105A patent/MY201694A/en unknown
- 2018-10-29 IL IL305485A patent/IL305485B2/en unknown
-
2019
- 2019-09-11 US US16/568,116 patent/US11033584B2/en active Active
-
2021
- 2021-03-12 US US17/200,301 patent/US11083753B1/en active Active
- 2021-07-30 US US17/390,673 patent/US11331346B2/en active Active
-
2022
- 2022-04-20 US US17/725,478 patent/US11590171B2/en active Active
- 2022-06-28 JP JP2022103225A patent/JP2022137112A/ja not_active Ceased
-
2023
- 2023-01-27 US US18/160,825 patent/US12398193B2/en active Active
- 2023-04-28 AU AU2023202582A patent/AU2023202582B2/en active Active
-
2024
- 2024-09-05 JP JP2024152864A patent/JP2024174943A/ja active Pending
-
2025
- 2025-07-30 US US19/285,909 patent/US20250361287A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014153470A2 (en) | 2013-03-21 | 2014-09-25 | Sangamo Biosciences, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| WO2017106528A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the t cell receptor |
Non-Patent Citations (2)
| Title |
|---|
| NATURE,2021年03月02日,Vol.543,p.113-117 |
| PNAS,2015年,Vol.112,p.10437-10442 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11331346B2 (en) | Targeted replacement of endogenous T cell receptors | |
| JP2022519595A (ja) | 免疫療法の改善のための遺伝子標的の組み合わせ | |
| JP2021518162A (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| JP2021518161A (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| JP2021518161A6 (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| JP2021518160A (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| KR20200018645A (ko) | 표적화된 비-바이러스 dna 삽입 | |
| CN111093679A (zh) | 用于条件调控基因表达的方法和系统 | |
| KR20190075019A (ko) | 조작된 면역조절요소 및 이에 의해 변형된 면역 활성 | |
| US20210207174A1 (en) | Genetic engineering of endogenous proteins | |
| KR20170106486A (ko) | 일차 조혈 세포에서의 단백질 전달 | |
| JP2022519070A (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| TW202542303A (zh) | 經工程改造之t細胞 | |
| EA050071B1 (ru) | Направленная замена эндогенных т-клеточных рецепторов | |
| HK40115874A (en) | Targeted replacement of endogenous t cell receptors | |
| HK40037128A (en) | Targeted replacement of endogenous t cell receptors | |
| BR112020008201B1 (pt) | Método in vitro ou ex vivo para edição do genoma de uma célula t humana primária, composição, população de células t, e uso de uma célula t |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200629 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200608 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211028 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211028 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20211028 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220520 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220530 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220628 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7101419 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |